Hanmi Pharmaceutical CEO Hwang Sangyeon Makes First Official Move After Inauguration with Production and R&D Inspections

Visits Paltan and Pyeongtaek Plants to Inspect Production Processes Firsthand
Meeting with Researchers at Dongtan R&D Center
Emphasizes Ongoing Commitment to New Drug Development

Hwang Sangyeon, the new CEO of Hanmi Pharmaceutical, visited the manufacturing site as his first official duty after taking office.

On the 1st, Hwang Sang-yeon, the newly appointed CEO of Hanmi Pharmaceutical, visited the Pyeongtaek Bioplant to inspect the biopharmaceutical production site and took commemorative photos with employees. Hanmi Pharmaceutical

According to Hanmi Pharmaceutical on April 2, CEO Hwang visited the Paltan Smart Plant, Pyeongtaek Bio Plant, and Dongtan R&D Center in succession the previous day. He checked the production processes and research status, and communicated directly with employees.

At the Paltan plant, he inspected the ICT-based pharmaceutical manufacturing processes and the RFID logistics system, and reviewed on-site operations to maintain GMP standards. At the Pyeongtaek Bio Plant, he toured the large-scale biopharmaceutical production facilities and the pre-filled syringe production line.

At the Dongtan R&D Center, he held a meeting with researchers to hear about the research environment and support needs. He also expressed his commitment to the continued development of ongoing new drug projects.

On the day of his inauguration, CEO Hwang also attended an employee event at Beijing Hanmi Pharmaceutical, continuing his efforts to communicate within the organization.

CEO Hwang stated, "I will focus on management activities based on law and common sense, strengthen decision-making centered on the field and employees, and pursue rational management through collaboration within the group."

This content was produced with the assistance of AI translation services.